HyperGH 14X Reviews 2025: Best HGH Supplements for Men
GLASGOW, United Kingdom, April 19, 2025 (GLOBE NEWSWIRE) -- Nutritional supplements for men are big business that generate billions annually. The most prominent issue is that the industry is unregulated, which means that there are many HGH products that do not work and, in some cases, are unsafe. This has become an increasingly problematic issue with HGH releasers.Synthetic HGH can build muscle mass, reduce body fat, improve bone density and increase exercise capacity. However, it is only available via a subscription and has some serious health concerns associated with it, including kidney disease, pituitary tumors, muscle wasting and so forth.
Many men who are not candidates for prescription HGH injections or are concerned with the potential side effects have turned to HGH booster supplements instead. As mentioned, the problem is that that many of these products do nothing at all. This report explores four products that do work. It also considers what each product does well and which types of men should consider taking them.
The Best HGH Supplements for Men
#1. HyperGH 14X — Best for Muscle Building
A Closer Look at the Top Three HGH Supplements on the Market
HyperGH 14X — Best for Muscle BuildingAs the health and fitness industry continues to embrace natural alternatives to synthetic hormones, HyperGH 14X has quickly gained recognition as one of the top HGH supplements on the market. Whether you're aiming to bulk up, shred fat, improve recovery, or just feel more energetic and youthful, HyperGH 14X promises to deliver powerful results — naturally.
What Is HyperGH 14X?
HyperGH 14X is a natural human growth hormone (HGH) supplement designed to stimulate your body's own production of HGH. It's not a synthetic hormone. Instead, it uses a scientifically-backed blend of amino acids and other nutrients that trigger your pituitary gland to ramp up HGH production naturally.
This two-part system includes:
Daily Capsules
Oral Spray (Alpha GPC Enhanced)
Together, they work synergistically to maximize results.
How Does HyperGH 14X Work?
HGH plays a vital role in muscle growth, fat metabolism, recovery, energy levels, and even skin and sleep quality. As we age — especially past 30 — natural HGH levels decline, leading to slower recovery, stubborn fat, decreased libido, and reduced performance.
HyperGH 14X supports:
Natural HGH production
Faster post-workout recovery
Increased lean muscle gains
Enhanced fat burning
Improved sleep and workout performance
Unlike injectable HGH (which is costly and requires a prescription), HyperGH 14X offers a legal and side-effect-free alternative for fitness enthusiasts and aging men alike.
Key Ingredients in HyperGH 14X
HyperGH 14X boasts a clinically formulated blend of HGH precursors and supportive compounds. Some of the standout ingredients include:
L-Arginine – Enhances HGH levels and boosts exercise performance
L-Glutamine – Supports recovery, metabolism, and immunity
L-Glycine – Stimulates the pituitary gland to secrete more HGH
L-Tyrosine – Supports mental focus and stress regulation
Astragalus Root Extract – Boosts immune function and metabolism
GABA (Gamma-Aminobutyric Acid) – Enhances deep sleep and HGH production
Alpha GPC in the spray – Improves cognitive function and HGH secretion
This carefully curated formula ensures maximum natural support for HGH release without any synthetic additives.
Benefits of Using HyperGH 14X
- Build Lean Muscle FasterWith improved HGH levels, muscle protein synthesis increases, allowing for faster and more effective muscle gains.
- Accelerate Fat LossHyperGH 14X helps activate the body's fat-burning processes, especially around the abdomen — one of the most stubborn areas for men.
- Faster Recovery TimeEnhanced recovery means less soreness, more gains, and consistent performance.
- Better Sleep & MoodQuality sleep is essential for growth hormone release. Users report deeper sleep, better mood, and reduced stress levels.
- Youthful Energy & VitalityMany users experience a noticeable difference in energy levels, motivation, and overall vitality.
Is HyperGH 14X Safe?
Yes. HyperGH 14X is manufactured in a cGMP-compliant facility and contains no synthetic HGH or harmful stimulants. Most users tolerate it very well with no reported side effects.
However, if you're on medication or have underlying health conditions, it's always wise to consult your doctor before starting any new supplement.
Pros:
Fast results
Helps build lean muscle
Available as a spray or a capsule
High success rate among active men
Cons:
Pricey
Dairy and soy allergy warning
Pricing & Special Offers
Leading Health Edge takes a similar approach to both of its products. The base price is $69.99 per bottle, which is a bit higher than the norm. You do have bulk purchasing options, and these range from two to six months. However, they do not result in significant savings. Buying five bottles lowers the price to the base price of HGH-X2, and buying six bottles saves you about $6. In addition, you have to purchase at least three bottles in order to get the free worldwide shipping. Otherwise, you have to pay for it.
Refund Policy
HyperGH 14X has one of the best refund policy. You have 67 days from receiving your order to request a refund. You must then return all opened and unopened bottles or sprays. Upon receipt, the company will refund your entire purchase amount but not any shipping or handling fees.
>Take your workouts to the next level and build muscle faster than ever before with HyperGH 14X!
What Are HGH Releasers and How Do They Work?
HGH supplements are often compared with synthetic HGH injections, but injections are used to elevate HGH levels in an artificial way and are generally used for people with low HGH in order to achieve balanced HGH levels. There is also HGH precursor therapy. This approach does not elevate HGH levels in an artificial manner but rather triggers the pituitary gland to create and release more HGH naturally.
The products we have reviewed here are HGH precursors. These are also known as boosters, stimulants and releasers, and we use these terms interchangeably throughout this report. As mentioned, releasers work by encouraging your pituitary gland to release more HGH. HGH precursor therapy performed by a doctor requires the injection of peptides, but supplements do not.
Every HGH booster supplement on the market works a bit different, but the general concept is the same: elevate the levels of particular amino acids in your body. Often, as is the case with HGH-X2, the medicinal chemists who design the product will target those amino acids that have been clinically proven to trigger the release of HGH. These are the amino acids that makes up those peptides used in HGH precursor therapy. There are also some amino acids and plant extracts theorized to trigger the release of HGH, and some products, including some on our list, feature those compounds as well.
Signs of Low HGH
The term low HGH is often referred to inappropriately in the supplement world. Adults can have an HGH deficiency, which is a medical condition that must be treated by a doctor. If you suspect that you have an HGH deficiency, it is imperative that you see a doctor rather than try HGH boosters.
HGH levels peak during puberty. Your adult HGH levels persist until about age 30, at which point they begin to decline. When they start to decline, that drop-off continues and never ends. This state of decline is generally what is meant when people refer to low HGH. The signs include:
Cognitive decline
Lower bone density
Wrinkles and sagging skin
Weight gain and increased body fat
Loss of muscle mass and difficulty gaining lean muscle
>>Click here to see HyperGH 14X Official Website
HGH Supplements Vs. Synthetic HGH Injections
Synthetic HGH injections boosts your HGH levels by introducing synthetic HGH to your system. These injections require a prescription and are only prescribed for specific medical conditions. The most prevalent is the muscle-wasting disease that arises from HIV/AIDS. It is prescribed for children and adults who suffer from HGH deficiencies and HGH insufficiencies. It is also used to treat infants who are born small for their gestational. Although not in the United States, HGH is used to heal faster from injuries and surgeries. Some similar HGH treatments are undergoing clinical review in the U.S.
HGH supplements are HGH releasers, which means that they trigger your pituitary gland to release more and thus create more HGH. These kinds of HGH stimulants help increase your HGH naturally but will generally not be effective for a person suffering from an HGH deficiency or insufficiency. As people age and their body's release less HGH, it is not because the pituitary gland lacks the ability. Releasers work in this context because they are just activating the gland to return to its normal adult state.
What to Look for When Buying Top Human Growth Hormone Supplements
If you want to try taking an HGH supplement, we strongly encourage you to try HyperGH 14X, which we are confident is the best HGH supplement on the market. If not HyperGH 14X, then try one of the other HGH boosters we have showcased here since they are proven to work. If you prefer to try some of the other products on the market, here are a couple of key items to keep in mind:
1. The Company and/or Brand
There are a lot of fly-by-night companies and brands in the supplement world. The makers of HGH supplements that actually work are established, have been around for a while and can be vetted. If you have a problem telling which company makes it, avoid that product. If the product is attributed to an individual, it is most likely a scam. If the company has not been around a while or is not easily vetted, this is an indication that you should wait and let the product mature for a while.
2. The Price
HGH boosters are expensive to make for a number of reasons. The process of creating amino acids in a lab is expensive. The process of building the formula and packaging it is not cheap either. Another component is the consumer base. There is not widespread usage of HGH supplements. Therefore, these products are made in small batches, which elevates the price as well. This is the reason that the industry average for a single dose is about $2. Specials and bulk discounts are understandable. But be wary of any product sold at a base price that is less than $1.50 a dose and especially $1 a dose.
3. The Money-Back Guarantee
Money-back guarantees are quite common in the supplement industry. Since there is no regulation, this is a tool that companies have to demonstrate that they are making and selling their products in good faith. That is not to say that a refund policy guarantees a good product. It is a tool used by unscrupulous companies as well. Nevertheless, no refund policy is definitely a warning sign.
4. The Ingredients
There is a great deal of experimentation with HGH supplements. We do not want to suggest that a supplement needs a particular ingredient in order to be valid. It does not. But most supplements are developed based on clinical research going on in the U.S. and throughout the world. That means that the ingredients can be vetted. If you cannot vet an ingredient or have no idea why it may have been added, it is probably best to wait until more information becomes available to you.
>>Click here to see HyperGH 14X Official Website
Frequently Asked Questions
1. Do HGH Pills Contain Real Human Growth Hormone?
No. The term HGH pills is a misnomer that refers to HGH supplements, HGH releasers, HGH precursors, HGH boosters and so forth. None of these products contain actual HGH. Synthetic HGH is currently only available as an injection.
2. How Much Do Natural HGH Supplements Cost?
The industry average is $60 per bottle, and the average bottle has a 30-day supply. Be mindful that there are often special discounts available in addition to bulk discounts. Since HGH supplements are often taken over an extended period, we recommend purchasing in bulk for the savings.
3. Can Women Take HGH Releasers?
Absolutely. HGH is not exclusive to males. While HGH supplements are generally associated with men, women can get many benefits from the right HGH releaser. Be mindful that the data used for this report was acquired from male users, and thus, our findings do not necessary apply to females.
4. Can You Take HGH Boosters With Other Dietary Supplements?
Yes. You can mix HGH supplements with other nutritional supplements. As a general rule when taking multiple supplements, you should track the cumulative ingredients that you are taking in order to ensure that you are not exceeding the daily recommended limit for any particular ingredient.
5. Can You Take HGH Boosters With Medications?
There are no known negative interactions between medications and the four products discussed in this report. We cannot make a general comment one way or the other. However, even with the products presented here, it is best to consult with your physician and pharmacist first. One of the most likely interactions is that a medication will disrupt absorption of a supplement thus making it ineffective. Your pharmacist can help you to avoid this by optimizing the schedule for your doses.
6. Can You Find HGH for Sale in Stores Like GNC?
No. HGH is not technically a controlled substance as identified by the Controlled Substance Act. However, the 1990 Anabolic Steroids Control Act makes it illegal to possess or distribute for any purposes other than treating a medical condition. It cannot legally be sold in GNC.
7. Can You Buy Real HGH Online?
Yes. HGH is legal in many countries and thus sold online. However, it is not legal in the United States for those sites to sell HGH to Americans and for Americans to purchase HGH.
8. Can Growth Hormone Pills Make You Taller?
No. This is perhaps one of the most common misconceptions with HGH. Not even synthetic HGH can help adults grow taller because their growth plates have already hardened into bone. HGH can help children grow taller, and doing so is generally reserved for children with an HGH deficiency. HGH supplements will not work in this manner, however, and should not be given to children.
10. Are HGH Supplements Safer Than Somatropin Injections?
Somatropin is manmade human growth hormone or synthetic HGH. There are many side effects associated with synthetic HGH, which is why it requires a prescription and you must be carefully monitored by a doctor in order to ensure your long-term well-being. HGH supplements, on the other hand, are quite safe. They are sold over the counter and have no known side effects associated with them. Any side effects are generally the result of allergies and quite minor.
>>Click here to see HyperGH 14X Official Website
Final Thoughts
Although we did not list them in this report, we reviewed many different HGH supplements prior to drawing our conclusions. The sheer number of products with high failure rates and high customer dissatisfaction rates is even higher than we suspected it to be. The best HGH supplements for men listed here are even more impressive in that context because the success rates and customer satisfactions are very high for all of them.
As we mentioned earlier in the report, if you suspect that you are HGH deficient, do not take a supplement but rather go see a doctor. On the other hand, if you are a man 30 or up who is gaining fat, struggling to lose weight, having difficulty building muscle or experiencing issues in the bedroom, a best quality HGH supplement can have a transformative effect on your life. It is absolutely worth the money, and the money-back guarantees allow you to find out for yourself without any real risk.
Official Website: https://www.hypergh14x.com/Contact Details: HyperGH 14XContact Person: Steve DavidEmail: support@hypergh14x.comPhone: +1-250-999-0414Address: 12 Payne Street Glasgow G4 0LF United Kingdom
Disclaimer: These statements have not been reviewed by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Consult a healthcare professional before using any dietary supplement.
Disclosure: This article is for informational purposes only and should not be considered medical advice. It may contain affiliate links, which means we may earn a commission if you make a purchase through these links. Always seek guidance from a healthcare professional before beginning any new supplement regimen.
Photos accompanying this announcement are available at:https://www.globenewswire.com/NewsRoom/AttachmentNg/6488cb75-58f3-4920-9074-6f351f312fbfhttps://www.globenewswire.com/NewsRoom/AttachmentNg/f4e7f497-3842-476d-a9fa-618b5f980689Sign in to access your portfolio

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
LONDON, June 13, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 8,991 ACUT shares in the open market. This brings his total holding to 6,500,000 shares. About AccuStem AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor 'stemness,' we believe our tools will help care teams better understand the biology of each patient's cancer, leading to more informed decision making. For more information, please visit Investor and Media Contact:Wendy BlosserEmail: investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025
New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib REDWOOD CITY, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ('Biomea' or the 'Company') (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced updated preliminary clinical data from the ongoing Phase I COVALENT-103 trial of BMF-500 in adults with relapsed or refractory ('R/R') acute leukemia ('AL'). The results will be presented in a poster presentation at the European Hematology Association ('EHA') 2025 Congress in Milan, Italy. The presentation by Dr. Farhad Ravandi of The University of Texas MD Anderson Cancer Center will highlight emerging safety, pharmacokinetics/pharmacodynamics, and early clinical activity data for BMF-500, a highly selective covalent FMS-like tyrosine kinase 3 ('FLT3') inhibitor, in heavily pretreated patients with R/R AL. Key Results from the EHA 2025 Poster Presentation27 patients were enrolled across two study arms, Arm A (no CYP3A4 inhibitor; n=10) and Arm B (CYP3A4 inhibitor; n=17). All patients had R/R AL, with a median of 4 prior lines of therapy. 18 of the 27 patients were FLT3 mutations ('FLT3m') while the other 9 patients had FLT3 wild-type AL. Frequent co-mutations included WT1, TP53, IDH1/2, and NRAS. All 18 FLT3m patients had failed gilteritinib in the R/R setting and 9 of the 18 had received at least two FLT3 inhibitors prior to study entry. 26 of 27 (96%) enrolled patients had also received and failed the BCL2 inhibitor venetoclax. Key findings include: Clinical Activity Observed: 9 of 11 efficacy-evaluable FLT3m patients, defined as all patients enrolled who received at least one dose and had at least one disease assessment, showed bone marrow (BM) blast reduction; 5 of 11 achieved >50% BM blast reduction. 1 FLT3m patient achieved complete remission with incomplete hematologic recovery (CRi), sustained for 6 cycles. 1 FLT3m patient achieved morphologic leukemia-free state (MLFS); response is ongoing. 1 FLT3m patient met all criteria for partial response (PR) except platelet recovery; categorized as near PR. 2 of 4 efficacy-evaluable FLT3 wild-type patients achieved durable disease control ≥120 days, with treatment ongoing for one patient. Additional clinical improvements include reductions in peripheral blasts, transfusion dependency, and frequency of hydroxyurea use. Pharmacokinetics/Pharmacodynamics: FLT3 inhibition correlated with BMF-500 systemic exposures. Bone marrow and plasma concentrations of BMF-500 and its metabolites were comparable, suggesting good compartmental penetration. Survival: Median overall survival (mOS) among all treated FLT3m patients (n=18) was 3.8 months (Arm A) and 3.5 months (Arm B) during dose escalation. For the efficacy-evaluable FLT3m patients (n=12), the mOS for Arms A and B was 3.8 and 3.6 months, respectively during dose escalation. These survival durations compare favorably to historical mOS of 2.1 months in patients with R/R FLT3m acute myeloid leukemia ('AML') post-failure with both gilteritinib and venetoclax. 1 Ongoing Dose Escalation: Dose escalation continues at 200 mg BID (Arm A) and 75 mg BID (Arm B). Based on observed activity and tolerability, further evaluation is underway to determine optimal biologic dose ('OBD') and recommended Phase II dose ('RP2D'). Safety and Tolerability BMF-500 was generally well-tolerated across dose levels. No dose-limiting toxicities (DLTs), QT prolongation, or discontinuations due to treatment-related adverse events were reported. Escalation is ongoing without safety restrictions. 'The updated COVALENT-103 results continue to support the potential of BMF-500 as a selective, covalent FLT3 inhibitor,' said Mick Hitchcock, Ph.D., Interim Chief Executive Officer of Biomea Fusion. 'We are encouraged by the depth of bone marrow responses, the achievement of MLFS and CRi, and the early survival benefit in heavily pretreated patients with FLT3 mutations who had progressed following prior FLT3 inhibitor therapy. These data speak to BMF-500's potential to meaningfully improve outcomes in a high-risk AML population with no currently available treatment options.' Following completion of the COVALENT-103 dose escalation phase in R/R AL patients with FLT3m, Biomea plans to conclude its internal development of BMF-500 in oncology and is actively exploring strategic partnerships to advance the program. Poster Presentation Details Date/Time: Saturday, June 14 (18:30-19:30 CEST) Title: Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the COVALENT-103 Study (NCT05918692) Poster Number: PS1520 Presenter: Farhad Ravandi, M.D., University of Texas MD Anderson Cancer Center About COVALENT-103 COVALENT-103 is a multicenter, open-label, non-randomized trial seeking to evaluate the safety and efficacy of BMF-500, a twice daily oral treatment, in adult patients with R/R AL with FLT3 wild-type or FLT3m. The Phase I COVALENT-103 study aims to evaluate the safety and tolerability of BMF-500, determine the optimal biologic dose and recommended Phase II dose, and identify initial efficacy signals. Additional information about the Phase I clinical trial of BMF-500 can be found at using the identifier, NCT05918692. About BMF-500 BMF-500 is an investigational, orally bioavailable, covalent small molecule inhibitor of FLT3, discovered in-house using Biomea's proprietary FUSION™ System. Designed to be highly potent and selective, BMF-500 has demonstrated encouraging potential in extensive preclinical studies. Its kinase inhibitory profile indicates strong target selectivity, which may translate to a reduced risk of off-target effects. About Biomea FusionBiomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both designed to significantly improve the lives of patients with diabetes, obesity, and other metabolic diseases. We aim to cure. Visit us at and follow us on LinkedIn, X, and Facebook. Forward-Looking Statements Statements we make in this press release may include statements which are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development programs, including BMF-500, the potential of BMF-500 as a treatment for patients with FLT3m R/R AL, our research, development, partnership and regulatory plans, and the timing of such events may be deemed to be forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. Any forward-looking statements in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including the risk that preliminary or interim results of preclinical studies or clinical trials may not be predictive of future or final results in connection with future clinical trials and the risk that we may encounter delays in preclinical or clinical development, patient enrollment and in the initiation, conduct and completion of our ongoing and planned clinical trials and other research and development activities. These risks concerning Biomea's business and operations are described in additional detail in its periodic filings with the U.S. Securities and Exchange Commission (SEC), including its most recent periodic report filed with the SEC and subsequent filings thereafter. Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Reference: 1. Corley et al. (P1798) HemaSphere 2024;8(S1), 3339-3340. Contact: Meichiel Jennifer Weiss Sr. Director, Investor Relations and Corporate DevelopmentIR@


Business Upturn
5 hours ago
- Business Upturn
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
By GlobeNewswire Published on June 13, 2025, 11:30 IST Strasbourg (France), June 13, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors, scientists and leaders of the biotechnology ecosystem during the upcoming editions of: BIO International Convention 2025 , on June 16, in Boston, US; , on June 16, in Boston, US; Portzamparc – 2025 Mid&Small Caps Conference (hosted by BNP Paribas Group ), on June 18, in Paris, France; (hosted by ), on June 18, in Paris, France; International Neoantigen Summit , on June 24, 2025, in Amsterdam, Netherlands; , on June 24, 2025, in Amsterdam, Netherlands; International Academy of Oral Oncology 2025 (IAOO), on July 18, in Liverpool, UK. Following the positive clinical data on our individualized neoantigen cancer vaccine TG4050, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (see press release here), Transgene together with Prof. Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology), have discussed the data presented, the unmet medical need and current treatment landscape for patients suffering from head and neck cancers in a virtual event available on Transgene website and here. *** About Transgene Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities. With Transgene's myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC. With its proprietary platform Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Additional information about Transgene is available at: Follow us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene Contacts Disclaimer This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque') section of the Universal Registration Document, available on the AMF website ( or on Transgene's website ( Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Attachment 20250613_Transgene_Upcoming_Events_EN Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.